Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial).

Tripathi, D.; Handley, K.; Holden, L.; Abdali, Z.; Jowett, S.; Mathers, J.; Poyner, C.; Richardson, P.; Ferguson, J.; Rowe, I.

Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial).

All Authors

Tripathi, D.

Handley, K.

Holden, L.

Abdali, Z.

Jowett, S.

Mathers, J.

Poyner, C.

Richardson, P.

Ferguson, J.

Rowe, I.

LTHT Author

Rowe, Ian

LTHT Department

Abdominal Medicine & Surgery
Liver Unit
Hepatology

Publication Date

2025

Item Type

Journal Article
Multicenter Study
Randomised Controlled Trial
Comparative Study

Abstract

BACKGROUND: The superior efficacy of non-selective beta-blockers (NSBB) compared with variceal band ligation (VBL) in the primary prevention of variceal bleeding is uncertain. AIM: To compare carvedilol versus VBL for primary prevention of variceal bleeding. METHODS: CALIBRE was an investigator-initiated, multicentre, randomised, controlled, open-label trial. Participants were randomly assigned to 12.5 mg carvedilol once daily or VBL. Inclusion criteria were cirrhosis and medium to large oesophageal varices that had not bled. The primary outcome is any variceal bleeding within 1 year of randomisation. Secondary outcomes include survival, other complications of cirrhosis, quality of life, cost-effectiveness and adverse events. Recruitment closed early, mainly due to the impact of the pandemic. RESULTS: 265 participants (10% of the intended sample size) from 52 sites were randomised to carvedilol (n = 133) or VBL (n = 132) between 22 January 2019 and 31 August 2022. 5/133 participants (3.8%) in the carvedilol arm vs. 10/132 participants (7.6%) in the VBL arm experienced variceal bleeding (risk ratio 0.50 (95% confidence interval [CI]; 0.17-1.41); risk difference - 0.038 (95% CI; -0.094-0.017)). Serious adverse events occurred in one participant in each treatment arm, with no treatment-related deaths. Of the secondary outcomes, there were no statistically significant differences. Carvedilol was cheaper and resulted in slightly more quality-adjusted life years than VBL. CONCLUSIONS: The early terminated and, thus, underpowered CALIBRE trial showed no difference between carvedilol and VBL in the primary prevention of variceal bleeding in patients with cirrhosis and medium-to large-sized oesophageal varices. No untoward safety concerns were noted. TRIAL REGISTRATION: ISRCTN73887615.